Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's Disease: results of a randomized, double-blind, placebo-controlled phase 2a study